Back to mobile site

BMO Capital Starts Intercept Pharmaceuticals (ICPT) at Outperform

April 6, 2016 4:22 PM EDT Send to a Friend
BMO Capital initiates coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with a Outperform rating and a price target of $239.00.Analyst M ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login